Castle Biosciences Inc (CSTL)

$40.77 +1.13 (2.85%)
Market Cap 1.16B
Revenue (ttm) 332.07M
Net Income (ttm) 18.25M
EPS (ttm) N/A
PE Ratio 158.64
Forward PE N/A
Profit Margin 5.50%
Debt to Equity Ratio 0.02
Volume 410,700
Avg Vol 458,054
Day's Range N/A - N/A
Shares Out 29.19M
Stochastic %K 76%
Beta 1.06
Analysts Strong Sell
Price Target $44.62

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 866 788 9007
Address:
505 S. Friendswood Drive, Suite 401, Friendswood, United States
wiseman88
wiseman88 Jan. 13 at 2:41 PM
$CSTL preliminary reports show another strong quarter and finish to 2025. Expecting a good bump here until Feb earnings call.
0 · Reply
Quantumup
Quantumup Jan. 12 at 12:22 PM
Canaccord Genuity reiterated $CSTL Buy/$50: Here's what Canaccord Genuity had to say in its note to investors: https://x.com/Quantumup1/status/2010688023273341311?s=20
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 3:31 AM
$CSTL RSI: 56.79, MACD: 1.1543 Vol: 0.83, MA20: 39.19, MA50: 34.87 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TradeTracs
TradeTracs Dec. 30 at 12:54 AM
$CSTL - Strong recent earnings - Tight price action - Strong relative strength
0 · Reply
TradeTracs
TradeTracs Dec. 26 at 6:44 PM
$CSTL - Strong sector and theme - Strong recent earnings - Tight price action
0 · Reply
CityCurator
CityCurator Dec. 26 at 12:22 PM
$CSTL Risk appetite is present but conditioned on validation. Cash efficiency must trend upward while maintaining strategic flexibility. Overextension would degrade optionality during downturns. Execution quality will determine whether momentum is sustainable.
0 · Reply
SpinDoctorStox
SpinDoctorStox Dec. 24 at 12:35 PM
$CSTL Market attention is shifting toward whether external catalysts materialize before balance-sheet pressure intensifies. Clear inflection points are required to justify renewed interest.
0 · Reply
BioTechNoir
BioTechNoir Dec. 22 at 6:30 PM
$CSTL screaming to $50+
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 12:48 PM
Canaccord Genuity has updated their rating for Castle Biosciences ( $CSTL ) to Buy with a price target of 50.
0 · Reply
MichaelKTrades
MichaelKTrades Dec. 18 at 9:56 PM
Market action is mixed IMO. Weaker inflation leads to further rate cuts and weaker USD $. May explain why silver and gold are hitting new highs. $GFI looks decent coming out of a multi week base. Other set ups for pilot buys if we rally $CSTL HTF $SGHT $PLTR
0 · Reply
Latest News on CSTL
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Jan 11, 2026, 4:00 PM EST - 3 days ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2025, 7:00 AM EST - 26 days ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Dec 17, 2025, 7:00 AM EST - 4 weeks ago

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Dec 12, 2025, 7:00 AM EST - 4 weeks ago

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Dec 9, 2025, 7:00 AM EST - 5 weeks ago

Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Nov 17, 2025, 7:00 AM EST - 2 months ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Nov 14, 2025, 7:00 AM EST - 2 months ago

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 11, 2025, 7:00 AM EST - 2 months ago

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Why Castle Biosciences' Rally Might Just Be Getting Started

Nov 5, 2025, 8:02 AM EST - 2 months ago

Why Castle Biosciences' Rally Might Just Be Getting Started

Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:06 PM EST - 2 months ago

Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript

Castle Biosciences Reports Third Quarter 2025 Results

Nov 3, 2025, 4:07 PM EST - 2 months ago

Castle Biosciences Reports Third Quarter 2025 Results

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 3, 2025, 4:05 PM EST - 2 months ago

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Castle Biosciences to Participate in Upcoming Investor Conferences

Oct 28, 2025, 7:00 AM EDT - 2 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus

Oct 26, 2025, 3:05 PM EDT - 2 months ago

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Oct 24, 2025, 4:05 AM EDT - 2 months ago

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Oct 13, 2025, 7:00 AM EDT - 3 months ago

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Oct 1, 2025, 4:30 PM EDT - 3 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Sep 23, 2025, 7:00 AM EDT - 4 months ago

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025

Sep 17, 2025, 7:00 AM EDT - 4 months ago

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Sep 9, 2025, 7:00 AM EDT - 4 months ago

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential

Sep 2, 2025, 9:14 AM EDT - 4 months ago

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Aug 25, 2025, 7:00 AM EDT - 5 months ago

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 10:21 PM EDT - 5 months ago

Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

Castle Biosciences Reports Second Quarter 2025 Results

Aug 4, 2025, 4:05 PM EDT - 5 months ago

Castle Biosciences Reports Second Quarter 2025 Results

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Jul 25, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test

Jul 23, 2025, 7:00 AM EDT - 6 months ago

FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

Jul 17, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

Jul 14, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Jun 16, 2025, 4:30 PM EDT - 7 months ago

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Jun 11, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

Jun 4, 2025, 7:00 AM EDT - 8 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

May 29, 2025, 4:30 PM EDT - 8 months ago

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 8 months ago

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

May 9, 2025, 7:00 AM EDT - 8 months ago

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle Biosciences Celebrates Skin Cancer Awareness Month

May 7, 2025, 7:00 AM EDT - 9 months ago

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:58 PM EDT - 9 months ago

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

Castle Biosciences Reports First Quarter 2025 Results

May 5, 2025, 4:06 PM EDT - 9 months ago

Castle Biosciences Reports First Quarter 2025 Results

Castle Biosciences to Acquire Previse

May 5, 2025, 4:05 PM EDT - 9 months ago

Castle Biosciences to Acquire Previse

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

May 2, 2025, 4:30 PM EDT - 9 months ago

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Apr 30, 2025, 5:00 PM EDT - 9 months ago

New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Apr 28, 2025, 7:00 AM EDT - 9 months ago

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Apr 25, 2025, 4:15 PM EDT - 9 months ago

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Apr 8, 2025, 7:00 AM EDT - 10 months ago

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Apr 7, 2025, 7:00 AM EDT - 10 months ago

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test

Apr 3, 2025, 7:00 AM EDT - 10 months ago

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Apr 1, 2025, 4:30 PM EDT - 10 months ago

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

Mar 28, 2025, 4:15 PM EDT - 10 months ago

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Mar 7, 2025, 7:00 AM EST - 11 months ago

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:09 PM EST - 11 months ago

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

wiseman88
wiseman88 Jan. 13 at 2:41 PM
$CSTL preliminary reports show another strong quarter and finish to 2025. Expecting a good bump here until Feb earnings call.
0 · Reply
Quantumup
Quantumup Jan. 12 at 12:22 PM
Canaccord Genuity reiterated $CSTL Buy/$50: Here's what Canaccord Genuity had to say in its note to investors: https://x.com/Quantumup1/status/2010688023273341311?s=20
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 3:31 AM
$CSTL RSI: 56.79, MACD: 1.1543 Vol: 0.83, MA20: 39.19, MA50: 34.87 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TradeTracs
TradeTracs Dec. 30 at 12:54 AM
$CSTL - Strong recent earnings - Tight price action - Strong relative strength
0 · Reply
TradeTracs
TradeTracs Dec. 26 at 6:44 PM
$CSTL - Strong sector and theme - Strong recent earnings - Tight price action
0 · Reply
CityCurator
CityCurator Dec. 26 at 12:22 PM
$CSTL Risk appetite is present but conditioned on validation. Cash efficiency must trend upward while maintaining strategic flexibility. Overextension would degrade optionality during downturns. Execution quality will determine whether momentum is sustainable.
0 · Reply
SpinDoctorStox
SpinDoctorStox Dec. 24 at 12:35 PM
$CSTL Market attention is shifting toward whether external catalysts materialize before balance-sheet pressure intensifies. Clear inflection points are required to justify renewed interest.
0 · Reply
BioTechNoir
BioTechNoir Dec. 22 at 6:30 PM
$CSTL screaming to $50+
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 12:48 PM
Canaccord Genuity has updated their rating for Castle Biosciences ( $CSTL ) to Buy with a price target of 50.
0 · Reply
MichaelKTrades
MichaelKTrades Dec. 18 at 9:56 PM
Market action is mixed IMO. Weaker inflation leads to further rate cuts and weaker USD $. May explain why silver and gold are hitting new highs. $GFI looks decent coming out of a multi week base. Other set ups for pilot buys if we rally $CSTL HTF $SGHT $PLTR
0 · Reply
IN0V8
IN0V8 Dec. 15 at 3:14 PM
$CSTL https://www.globenewswire.com/news-release/2025/12/09/3202211/0/en/Expert-Melanoma-Panel-Recommends-Castle-Biosciences-DecisionDx-Melanoma-as-a-Best-Practice-Tool-for-Managing-Patients-with-Melanoma.html
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 11:07 AM
BTIG has adjusted their stance on Castle Biosciences ( $CSTL ), setting the rating to Buy with a target price of 38 → 50.
0 · Reply
Dream2121
Dream2121 Dec. 4 at 2:10 AM
$CSTL $70 by 3rd Q 2026
0 · Reply
BioTechNoir
BioTechNoir Nov. 25 at 5:45 PM
$CSTL go baby
0 · Reply
Dream2121
Dream2121 Nov. 23 at 3:54 PM
$CSTL
0 · Reply
BioTechNoir
BioTechNoir Nov. 21 at 3:56 PM
$CSTL 52 week high!
0 · Reply
Dream2121
Dream2121 Nov. 21 at 1:03 PM
$CSTL
0 · Reply
NVDAMillionaire
NVDAMillionaire Nov. 18 at 7:54 AM
$CSTL Outstanding article that hits the mark on CSTL's current state. So if you want to refresh your CSTL insights or learn about CSTL from scratch, this is a must read. https://beyondspx.com/quote/CSTL/analysis/castle-biosciences-precision-diagnostics-powering-growth-amidst-reimbursement-headwinds-cstl
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 12:02 AM
$CSD $CSIQ $CSTL $CTAS $CTEC
0 · Reply
FORECAST_ONE
FORECAST_ONE Nov. 14 at 12:07 PM
$CSTL - New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node PositivitySecond study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomes
0 · Reply
Leadballoon
Leadballoon Nov. 8 at 3:15 AM
$CSTL https://www.youtube.com/watch?v=uqZZIDk2c_Y MaetSOLD curse.
0 · Reply
Leadballoon
Leadballoon Nov. 7 at 11:50 AM
$CSTL Flurries, waves, pounding of keyboards- Cramer voice SELL, SELL, SELL coming in the next week from MaetSOLD= never fails.
1 · Reply